PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 67 | 5 | 303–310
Article title

Ekspresja czynnika VEGF i receptora R1 w mięśniakach macicy kobiet w różnym wieku

Content
Title variants
EN
Expression of VEGF factor and R1 receptor in uterine myomas in women of different age
Languages of publication
PL
Abstracts
EN
Uterine myomas are the most common benign neoplasms of female reproductive organs. These neoplasms depend upon the impact of steroidal sex hormones – estrogen and progesterone. In uterine myoma cells a disturbed expression of some cytokines and factors is found, including angiogenic factors. The aim of the study was to evaluate the VEGF factor and VEGF-R1 receptor expression in uterine myomas. In the study there were 20 women with myomatous alterations in the uterus, including 10 women in reproductive age and 10 women in perimenopausal age. The study material consisted of tissue specimens taken from the myoma and specimens taken from normal myometrium. Evaluation of the VEGF factor and R1 receptor expression was conducted by means of immunohistochemical staining, using the ABC technique. In the evaluated cells with uterine myoma, both in young women and those in perimenopausal age, a significant increase in VEGF expression was found. This expression was independent of the myoma size. Moreover, a significantly higher VEGF-R1 expression was found in large myomas compared to small ones. The high VEGF factor expression level in women in perimenopausal age may indicate an additional local process of estrogen synthesis. The high VEGF-R1 expression in large myomas may suggest a direct stimulation of myoma growth affected by VEGF.
PL
Mięśniaki macicy należą do najczęstszych łagodnych nowotworów żeńskich narządów płciowych. Są to nowotwory zależne od wpływu steroidowych hormonów płciowych – estrogenów i progesteronu. W komórkach mięśniaków macicy stwierdza się zaburzoną ekspresję niektórych cytokin i czynników, w tym czynników angiogennych. Celem badań była ocena ekspresji naczyniowo-śródbłonkowego czynnika wzrostu VEGF (vascular endothelial growth factor) i receptora VEGF-R1 (vascular endothelial growth factor receptor 1) w mięśniakach macicy. Badaniem objęto 20 kobiet ze zmianami mięśniakowatymi w macicy, w tym 10 w wieku rozrodczym i 10 w wieku okołomenopauzalnym. Materiał do badań stanowiły wycinki tkankowe pobrane z mięśniaka oraz próbki pobrane z prawidłowego miometrium. Ekspresję czynnika VEGF i receptora R1 oceniano na podstawie barwienia immunohistochemicznego, wykorzystując technikę ABC. W ocenianych typach komórek macicy z mięśniakami, zarówno u kobiet młodych, jak i w wieku okołomenopauzalnym stwierdzono wyraźny wzrost ekspresji VEGF. Ekspresja ta była niezależna od wielkości mięśniaka. Stwierdzono także wyraźnie wyższą ekspresję VEGF-R1 w mięśniakach dużych niż w małych. Wysoki poziom ekspresji czynnika VEGF u kobiet w wieku okołomenopauzalnym może wskazywać na dodatkowy lokalny proces syntezy estrogenów. Wysoka ekspresja VEGF-R1 w mięśniakach dużych może świadczyć
Keywords
Discipline
Year
Volume
67
Issue
5
Pages
303–310
Physical description
References
  • 1. Flake G.P., Andersen J., Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ. Health Perspect. 2003; 111: 1037–1054.
  • 2. Marshall L., Spiegelman D., Barbieri R. i wsp. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet. Gynecol. 1997; 90: 967–973.
  • 3. Wise L.A., Palmer J.R., Harlow B. i wsp. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women’s. Health Study Hum. Reprod. 2004; 19: 1746–1754.
  • 4. Arici A., Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am. J. Obstet. Gynecol. 2003; 188: 76–83.
  • 5. Esteban J.M., Allen W.M., Schaerf R.H. Benign metastasizing leiomyoma of the uterus: histologic and immunohistochemical characterization of primary and metastatic lesions. Arch. Pathol. Lab. Med. 1999; 123: 960–962.
  • 6. Schwartz S.M., Marshall L.M., Baird D.D. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ. Health Perspect. 2000; 108: 821–827.
  • 7. Grosiki S., Grosika A., Hołowiecki J. Kliniczne znaczenie angiogenezy i czynników ją modyfikujących w onkohematologii. Wiad. Lek. 2007; LX: 39–46.
  • 8. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004; 25: 581–611.
  • 9. Jain R.K. Normalization of tumor vasculature: an emerging view of anti-angiogenic therapy. Science 2005; 307: 58–62.
  • 10. Barańska P., Jerczyńska H., Pawłowska Z. Vascular endothelial growth factor-structure and functions. Post. Biochem. 2005; 51: 12–21.
  • 11. Gruchlik A., Chodurek E., Domal-Kwiatkowska D., Dzierżewicz Z. VEGF-A – celem antyangiogennej terapii przeciwnowotworowej. Post. Biol. Kom. 2007; 34: 557–580.
  • 12. Scadden D.T. Cancer stem cells refined. Nat Immunol 2004; 5: 701–703.
  • 13. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev 2004; 25: 581–611.
  • 14. Jain R.K. Normalization of tumor vasculature: an emerging view of anti-angiogenic therapy. Science 2005; 307: 58–62.
  • 15. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006; 12: 5018–5022.
  • 16. Dvorak H.F. Angiogenesis: Update 2005. J. Thromb. Haemost. 2005; 3: 1835–1842.
  • 17. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006; 12: 5018–5022.
  • 18. Dikov M.M., Ohm J.E., Ray N. i wsp. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 2005; 174: 215–222.
  • 19. Hague S., Zhang L., Oehler M.K. i wsp. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin. Cancer Res. 2000; 6: 2808–2814.
  • 20. Ciarmela P., Islam M.S., Reis F.M. i wsp. Growth factors and myome-trium: biological effects in uterine fibroid and possible clinical implications. Hum. Reprod. Update 2011; 17: 772–790.
  • 21. Yu L., Moore A.B., Dixon D. Receptor tyrosine kinases and their hormonal regulation in uterine leiomyoma. Semin. Reprod. Med. 2010; 28: 250–259.
  • 22. Maruo T., Ohara N., Wang J. i wsp. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum. Reprod. Update. 2004; 10: 207–220.
  • 23. Hickey M., Lau T.M., Russell P., Fraser I.S., Rogers P.A. Microvascular density in conditions of endometrial atrophy. Hum. Reprod. 1996; 11: 2009–2013.
  • 24. Hickey M., Pillai G., Higham J.M. i wsp. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum. Reprod. 2003; 18: 1100–1106.
  • 25. Gentry C.C., Okolo S.O., Fong L.F. i wsp. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin. Sci. (Lond) 2001; 101: 691–695.
  • 26. Brown L.F., Detmar M., Tognazzi K. i wsp. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 1997; 76: 245–255.
  • 27. Dixon D., He H., Haseman J.K. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect. 2000; 108(Suppl 5): 795–802.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-2081a18a-982c-4b58-874f-0e3b773f0652
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.